The Garvan-Weizmann Partnership

“The Garvan-Weizmann Partnership is truly synergistic – an example of a collaboration that is greater than the sum of its parts.  It is a collaboration that will positively impact people across the globe in our lifetime.” 

Jillian Segal AO

Launched in 2016, the Partnership between the Weizmann Institute of Science and Garvan Institute of Medical Research, based in Sydney has harnessed the complementary expertise of these two world-class research institutes through joint programs, staff and student exchange and the use of cutting-edge technologies.  This has enabled Weizmann and Garvan scientists to uncover entirely new insights into autoimmune diseases, cancers, type 2 Diabetes and genomics.

The Garvan-Weizmann Partnership is particularly momentous as the Weizmann Institute is a global leader in multidisciplinary basic research and Garvan’s focus is on translational research. Together their complementary strengths enable scientists to answer some of science and medicine’s greatest questions faster than ever before in the areas of biomedical research, genomic medicine and genomic education.

The strategic direction of the partnership’s research is provided by a steering committee made up of senior scientific management from both Institutes. Currently underway, the Partnership has collaborative projects focussing on cancer (particularly breast cancer, melanoma, prostate cancer and multiple myeloma), on autoimmune diseases (including rheumatoid arthritis, lupus and multiple sclerosis to name a few, on cancer immunotherapies and personalised medicine for prediabetes.

Education is also a key part of the Partnership, with programs for scientific exchange between the Institutes and education for the greater community to advance the understanding of genomics through molecular visualisation and animation.

“The scientists and their teams collaborating within the Garvan-Weizmann Partnership are transforming research and importantly outcomes for individuals. The potential to deliver on highly personalised medicine based on a person’s genome is closer than ever.” 

Stephen Chipkin, Chair, Weizmann Australia.